Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

This open-label trial is composed of two periods: Induction and Extension. All eligible
patients will be enrolled into the 12-Week Induction period and receive study medication.
Patients who complete the Induction period may then be eligible to enter the 100-Week
Extension period where they will continue to receive study medication.

Key Inclusion Criteria:

- Crohn's disease (CD) confirmed by endoscopy and histology

- Active disease as evaluated by Crohn's Disease Activity Index Score and Simple
Endoscopic Score for CD

- Inadequate response to aminosalicylates, corticosteroids, immunomodulators or biologic
therapy

Key Exclusion Criteria:

- Diagnosis of ulcerative colitis or indeterminate colitis

- Known strictures/stenosis leading to symptoms of obstruction

- Current stoma or need for ileostomy or colostomy

- Clinically relevant cardiovascular conditions or other relevant diseases that could
impact the implementation or interpretation of the trial, or put the patient at risk

- History of uveitis or known macular edema

- History of colonic dysplasia